10 October 2024 Machine learning-enabled drug discovery and development company insitro has announced the execution of three strategic agreements with Eli Lilly.
London-listed Affimer developer Avacta has signed a collaboration and license agreement with AffyXell Therapeutics, a new joint venture formed together with Daewoong Pharmaceutical. 3 February 2020
Israeli drugmaker Teva Pharmaceutical Industries and its partner for the Japanese market, Otsuka Pharmaceutical, have edged closer to approval for Ajovy (fremanezumab) in the Asian country. 3 February 2020
Shares of US biopharma firm Orgenesis rocketed more than 35% to $6.77 in pre-market trading today, after announcing that Catalent has agreed to acquire MaSTherCell Global, a contract development manufacturing organization (CDMO) subsidiary of Orgenesis, which is also backed by Great Point Partners and SFPI-FPIM. 3 February 2020
The European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for belantamab mafodotin in relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody. 3 February 2020
New Jersey, USA-based oncology giant Bristol-Myers Squibb has withdrawn a European application to market Opdivo (nivolumab) and Yervoy (ipilimumab) for certain people with advanced non-small cell lung cancer (NSCLC). 3 February 2020
On Friday, the US Food and Drug Administration approved Palforzia (Peanut [Arachis hypogaea] allergen powder-dnfp) as the first ever treatment for patients with peanut allergy. 1 February 2020
Shares of US biotech giant Amgen were down 2.5% at $220.56 in after-hours trading on Thursday, after the company announced fourth-quarter and full-year 2019 financial results year. 31 January 2020
Dutch rare disease specialist ProQR Therapeutics (Nasdaq: PRQR) has been given Rare Pediatric Disease (RPD) designation for its candidate QR-421a. 30 January 2020
US biotech Alexion Pharmaceuticals today announced financial results for the fourth quarter and full year of 2019 which were above expectations, but its full year sales forecast missed, sending the firm’s shares down nearly 4.7% to $101.85 in mid-morning trading. 30 January 2020
US biotech major Biogen today reported full year and fourth quarter 2019 financial results which beat expectations and saw the firm’s shares up 2.15% at $288.60 in pre-market trading. 30 January 2020
Shares of USA-based Inovio Pharmaceuticals were up more than 15% at $4.74 pre-market today, as the company revealed it is collaborating with Beijing Advaccine Biotechnology Co to advance the development in China of INO-4800, Inovio's vaccine against the recently emerged strain of coronavirus (2019-nCoV) that has killed numerous people and infected thousands more in China to date. 30 January 2020
Olipudase alfa, an investigational recombinant human acid sphingomyelinase, demonstrated positive results in two separate clinical trials evaluating olipudase alfa for the treatment of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients. 30 January 2020
The European Commission (EC) has approved a second indication in prostate cancer for Erleada (apalutamide), from the Johnson & Johnson unit Janssen. 29 January 2020
Shanghai, China-based WuXi Biologics says it has increased efforts in enabling the development of multiple neutralizing antibodies for the current outbreak of a novel coronavirus (2019-nCoV), centered in Wuhan, China. 29 January 2020
The US Food and Drug Administation (FDA) has underlined its support for the field of gene therapies as it announces the release of guidelines for drug developers and manufacturers. 29 January 2020
Booster Therapeutics, a biotechnology company pioneering a new class of proteasome activator medicines to treat neurodegenerative and other diseases, has launched with the support of a $15 million financing. 11 October 2024
German cancer specialist Immatics has announced the pricing of its $150 million public offering, with Jefferies, BofA Securities, and Leerink acting as joint book runners. 11 October 2024
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Pfizer and BioNTech's latest COVID-19 vaccine, Comirnaty (KP.2). 11 October 2024
In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Nanoscope Therapeutics says that, following a productive FDA meeting with the US Food and Drug Administration (FDA) for its clinical program evaluating MCO-010 for the treatment of retinitis pigmentosa (RP), the company will commence with submission of a Biologics License Application (BLA) in the first quarter of 2025. 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
Gene therapy start-up GEMMA Biotherapeutics (GEMMABio) has announced a significant partnership with Brazil's Fiocruz, a key supplier for the Brazilian Ministry of Health. 10 October 2024
California’s Arda Therapeutics, a biotech focused on targeted cell depletion therapies for chronic diseases, has announced the successful completion of a $43 million Series A financing round. 9 October 2024
Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, has raised £80 million ($105 million) in a Series B financing. 9 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024